DelveInsight's "IBRANCE Market Size, Forecast, and Market Insight Report" highlights the details around IBRANCE, a CDK4/6 inhibitor. The report provides product descriptions, patent details, and ...

Bayer and Vividion Therapeutics to present latest research on their advancing oncology portfolio at AACR 2025 annual meeting: Berlin, Germany Wednesday, April 23, 2025, 10:00 Hrs ...

Cyclin D1–CDK4/6 phosphorylates GTSE1 in cancer cells, preventing its degradation and sustaining high levels across the cell cycle, which enhances proliferation and correlates with poor prognosis.

Beneath the surface of the tiny, see-through worm Caenorhabditis elegans, researchers have found new clues about how certain ...

Cancer drugs that inhibit CDK7 rapidly shut down pathways responsible for cell proliferation within minutes. For organs to ...

Relay Therapeutics, Inc.’s RLAY share price has dipped by 6.00%, which has investors questioning if this is right time to buy.

An artificial intelligence coding assistant declined to generate code for a user. Instead, it advised the developer to write the code themselves for better understanding. This incident sparked ...

The trial evaluated the effectiveness of AstraZeneca’s camizestrant, an investigational next-generation oral selective estrogen receptor degrader (SERD), in combination with one of three ...

Cyclacel Pharmaceuticals, Inc.’s CYCC share price has dipped by 15.89%, which has investors questioning if this is right time to buy.

Under the current federal-level credit, you can receive up to $2,000 per dependent child under age 17 from the child tax credit. The child tax credit is nonrefundable, meaning you can't receive ...